Clinical Trial Detail

NCT ID NCT01802632
Title AZD9291 First Time In Patients Ascending Dose Study
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult

No variant requirements are available.